Actively Recruiting
Study of Longitudinal Plasma PD-L1 Testing With Immunotherapy in Lung Cancer
Led by Ballad Health · Updated on 2025-02-28
30
Participants Needed
1
Research Sites
106 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a prospective pilot study to assess dynamic changes of plasma cell-free RNA (cfRNA) PD-L1 expression in patients with lung cancer undergoing immune checkpoint inhibitor (ICI) based therapy. Results will be correlated with radiographic assessment of immunotherapy treatment response and plasma NGS ctDNA.
CONDITIONS
Official Title
Study of Longitudinal Plasma PD-L1 Testing With Immunotherapy in Lung Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of stage IV or inoperable stage IIIB non-small cell lung cancer without planned primary radiation therapy
- Undergoing anti-PD-1 or anti-PD-L1 based immune checkpoint inhibitor treatment
- Eligible if receiving chemo-immune therapy or dual anti-PD-1/L1 with anti-CTLA-4 regimens including an anti-PD-1/L1 monoclonal antibody
- Documented informed consent obtained prior to participation
You will not qualify if you...
- No treatment with anti-PD-1 or anti-PD-L1 monoclonal antibody
- Planned primary radiation therapy
- Small-cell lung cancer histology
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Ballad Health Cancer Care
Kingsport, Tennessee, United States, 37660
Actively Recruiting
Research Team
C
Charles Mays, PhD, CCRP, CCRC
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here